重组人白细胞介素―11治疗恶性肿瘤化疗后血小板减少临床观察.docVIP

重组人白细胞介素―11治疗恶性肿瘤化疗后血小板减少临床观察 　　[摘要] 目的 研究重组人白细胞介素11（rh IL-11）治疗不同恶性肿瘤化疗后导致的血小板减少的效果和不良反应。 方法 采用单中心、非随机、自身对照、前瞻性研究，选取120例自2014年10月～2016年1月入院，化疗致血小板减少的恶性肿瘤患者为研究对象。入院后化疗引起血小板减少不采用药物改善的治疗周期为对照组， 同一患者在下一周期化疗引起血小板减少后给予rh IL-11 50 μg/（kg?d）皮下注射为试验组，比较试验组与对照组的疗效，试验组中不同肿瘤的疗效及不良反应。数据采用t检验、单因素方差分析和Kruskal-Wallis H检验。 结果 Kruskal-Waillis H检验分析（Hc=0.95，v=3，P 0.05）提示不同肿瘤的组间构成无差异。试验组中肺癌血小板恢复的效果优于对照组及其他恶性肿瘤（P 0.05），试验组用药11 d后血小板上升的幅度明显高于对照组（P 0.05），主??不良反应为发热、感冒样症状、乏力、心悸、恶心呕吐、皮疹、头痛等。 结论 rh IL-11对化疗引起的血小板减少症疗效显著， 临床不良反应可耐受， 未发生严重不良事件。 　　[关键词] 重组人白细胞-11；恶性肿瘤；化疗；血小板减少 　　[中图分类号] R730.53 [文献标识码] A [文章编号] 1674-4721（2016）08（c）-0189-04 　　[Abstract] Objective To investigate the efficacy and adverse effects of recombinant human interleukin- 11 for treatment of chemotherapy-induced thrombocytopenia in the patients with malignancy. Methods Monocenter， non-randomized， self-correlative， prospective study of 120 malignant tumor patients with thrombocytopenia in hospital from October 2014 to January 2016 were selected. Those patients who were not treated with drug in the early stage were treated as control group. The same patients were administered with 50 μg/（kg?d） rh IL-11 after the next chemotherapy and they were regarded as the experimental group. The changes′ extent of platelet and the adverse reactions in two groups were compared and observed. T-test， analysis of variance and Kruskal-Wallis H test were performed to analyse the data. Results Kruskal-Waillis H test analysis （Hc=0.95， v=3， P 0.05） suggested that there was no difference between the tumor types of each group. Recovery of platelets in lung cancer patients in experimental group was better than that in control group and other malignant tumors （P 0.05）. The extent of platelet in experimental group significantly higher than that in control group after 11 days （P 0.05）. The main adverse reactions were fever， cold symptoms， fatigue， palpitations， nausea， vomiting， rash， headache， etc. Conclusion rh IL-11 is an effective agent